Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

ATTR-CM is a rare heart failure type caused by transthyretin protein buildup, leading to heart muscle thickening and symptoms such as shortness of breath and heart failure. Hereditary ATTR-CM is more ...

Patients diagnosed with wild-type ATTR-CM on or before 65 years of age had better survival after diagnosis compared to patients who were diagnosed after 65 years. Wild-type transthyretin-mediated ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

Between 21.4% and 57.8% of patients from a real-world ATTR-CM cohort would have been eligible to take part in clinical trials testing disease-modifying therapies. Inclusion and exclusion criteria used ...

A promising new way to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM or -CA) has the field waiting in anticipation. Early-phase research suggests that the positron emission tomography ...

A new ACC Concise Clinical Guidance (CCG) report on "Transthyretin Cardiac Amyloidosis Evaluation and Management" provides updated strategies and best practices for clinicians, taking into account ...

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...